Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
{"title":"Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.","authors":"Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts","doi":"10.1111/ajco.70007","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.</p><p><strong>Methods: </strong>Patients received T-DM1 (3.6 mg/kg intravenously every 3 weeks) until death, disease progression, unacceptable toxicity, consent withdrawal, or up to a maximum of 12 months after the last patient's first visit, whichever occurred first. Safety was mainly assessed by the incidence and severity of adverse events (AEs). Efficacy was evaluated by progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). Patients were followed up posttreatment until 12 months or until lost to follow-up, withdrawn consent, or death.</p><p><strong>Results: </strong>A total of 70 eligible patients (median age [range]: 50.0 [27.0-75.0] years) received at least one dose of T-DM1 (median duration [range]: 32.0 [1.0-125.0] weeks). Adverse events in 21 (30.0%) patients were treatment-related. The most common treatment-related AEs and SAEs were thrombocytopenia (seven [10.0%] and three [4.0%] patients, respectively) and epistaxis (four [6.0%] and two [3.0%] patients, respectively). During the study, 10 (18.0%) patients died (disease progression: n = 6; AE: n = 3; and unknown reason: n = 1), while 2 patients died during the follow-up period. Median PFS was 14 months (95% confidence interval [CI]: 8.0, 17.0). Among 65 evaluable patients, 16 (23.0%) achieved partial responses; ORR was 23.0%.</p><p><strong>Conclusions: </strong>Trastuzumab emtansine was found to be safe and efficacious in the Indian patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.6 mg/kg intravenously every 3 weeks) until death, disease progression, unacceptable toxicity, consent withdrawal, or up to a maximum of 12 months after the last patient's first visit, whichever occurred first. Safety was mainly assessed by the incidence and severity of adverse events (AEs). Efficacy was evaluated by progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). Patients were followed up posttreatment until 12 months or until lost to follow-up, withdrawn consent, or death.
Results: A total of 70 eligible patients (median age [range]: 50.0 [27.0-75.0] years) received at least one dose of T-DM1 (median duration [range]: 32.0 [1.0-125.0] weeks). Adverse events in 21 (30.0%) patients were treatment-related. The most common treatment-related AEs and SAEs were thrombocytopenia (seven [10.0%] and three [4.0%] patients, respectively) and epistaxis (four [6.0%] and two [3.0%] patients, respectively). During the study, 10 (18.0%) patients died (disease progression: n = 6; AE: n = 3; and unknown reason: n = 1), while 2 patients died during the follow-up period. Median PFS was 14 months (95% confidence interval [CI]: 8.0, 17.0). Among 65 evaluable patients, 16 (23.0%) achieved partial responses; ORR was 23.0%.
Conclusions: Trastuzumab emtansine was found to be safe and efficacious in the Indian patients.
期刊介绍：
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
